About this Research Topic
Methods to monitor adequate immunosuppression post-transplant mostly have been reactionary. Immunosuppressants are lowered in the setting of infections and cancers while immunosuppressants would be increased in the setting of rejection. This difficult balancing act calls for better methods to personalize immunosuppressants for optimal post-transplant care.
Classical tools such as serum creatinine have been shown to be a late marker for kidney allograft dysfunction. Tools such as donor-derived cell-free DNA (dd-cfDNA) and gene expression have slowly emerged to help detect pre-clinical rejection but invasive kidney transplant biopsies are considered the gold standard for allograft rejection monitoring. This Research Topic aims to explore scientific evidence for available methods to monitor for adequate immunosuppression after kidney transplantation.
Classical tools such as serum creatinine have been shown to be a late marker for kidney allograft dysfunction. Tools such as donor-derived cell-free DNA (dd-cfDNA) and gene expression have slowly emerged to help detect pre-clinical rejection but invasive kidney transplant biopsies are considered the gold standard for allograft rejection monitoring. This Research Topic aims to explore scientific evidence for available methods to monitor for adequate immunosuppression after kidney transplantation.
Keywords: Kidney transplant, Renal Biopsy, Antibody Medicated Rejection, T-Cell Mediated Rejection, cell-free DNA (cfDNA), Gene expression, donor specific antibodies (DSAs)
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
